{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Idiopathic pulmonary fibrosis", "Natural products", "Therapeutic agents"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": [], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "37254717", "DateRevised": {"Year": "2023", "Month": "09", "Day": "02"}, "Article": {"ArticleDate": [{"Year": "2023", "Month": "05", "Day": "31"}], "Language": ["eng"], "ELocationID": ["10.4062/biomolther.2023.056"], "Journal": {"ISSN": "1976-9148", "JournalIssue": {"Volume": "31", "Issue": "5", "PubDate": {"Year": "2023", "Month": "Sep", "Day": "01"}}, "Title": "Biomolecules & therapeutics", "ISOAbbreviation": "Biomol Ther (Seoul)"}, "ArticleTitle": "Searching for Novel Candidate Small Molecules for Ameliorating Idiopathic Pulmonary Fibrosis: a Narrative Review.", "Pagination": {"StartPage": "484", "EndPage": "495", "MedlinePgn": "484-495"}, "Abstract": {"AbstractText": ["Idiopathic pulmonary fibrosis (IPF) can be defined as a progressive chronic pulmonary disease showing scarring in the lung parenchyma, thereby resulting in increase in mortality and decrease in the quality of life. The pathophysiologic mechanism of fibrosis in IPF is still unclear. Repetitive microinjuries to alveolar epithelium with genetical predisposition and an abnormal restorative reaction accompanied by excessive deposition of collagens are involved in the pathogenesis. Although the two FDA-approved drugs, pirfenidone and nintedanib, are under use for retarding the decline in lung function of patients suffered from IPF, they are not able to improve the survival rate or quality of life. Therefore, a novel therapeutic agent acting on the major steps of the pathogenesis of disease and/or, at least, managing the clinical symptoms of IPF should be developed for the effective regulation of this incurable disease. In the present review, we tried to find a potential of managing the clinical symptoms of IPF by natural products derived from medicinal plants used for controlling the pulmonary inflammatory diseases in traditional Asian medicine. A multitude of natural products have been reported to exert an antifibrotic effect <i>in vitro</i> and <i>in vivo</i> through acting on the epithelial-mesenchymal transition pathway, transforming growth factor (TGF)-\u03b2-induced intracellular signaling, and the deposition of extracellular matrix. However, clinical antifibrotic efficacy of these natural products on IPF have not been elucidated yet. Thus, those effects should be proven by further examinations including the randomized clinical trials, in order to develop the ideal and optimal candidate for the therapeutics of IPF."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacology, School of Medicine, Chungnam National University, Daejeon 35015, Republic of Korea."}, {"Identifier": [], "Affiliation": "Brain Korea 21 FOUR Project for Medical Science, Chungnam National University, Daejeon 35015, Republic of Korea."}], "LastName": "Kim", "ForeName": "Kyung-Il", "Initials": "KI"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacology, School of Medicine, Chungnam National University, Daejeon 35015, Republic of Korea."}, {"Identifier": [], "Affiliation": "Brain Korea 21 FOUR Project for Medical Science, Chungnam National University, Daejeon 35015, Republic of Korea."}], "LastName": "Hossain", "ForeName": "Rajib", "Initials": "R"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacology, School of Medicine, Chungnam National University, Daejeon 35015, Republic of Korea."}, {"Identifier": [], "Affiliation": "Brain Korea 21 FOUR Project for Medical Science, Chungnam National University, Daejeon 35015, Republic of Korea."}], "LastName": "Li", "ForeName": "Xin", "Initials": "X"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Smith Liberal Arts College and Department of Addiction Science,Graduate School, Sahmyook University, Seoul 01795, Republic of Korea."}], "LastName": "Lee", "ForeName": "Hyun Jae", "Initials": "HJ"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacology, School of Medicine, Chungnam National University, Daejeon 35015, Republic of Korea."}, {"Identifier": [], "Affiliation": "Brain Korea 21 FOUR Project for Medical Science, Chungnam National University, Daejeon 35015, Republic of Korea."}], "LastName": "Lee", "ForeName": "Choong Jae", "Initials": "CJ"}], "PublicationTypeList": ["Journal Article", "Review"]}, "MedlineJournalInfo": {"Country": "Korea (South)", "MedlineTA": "Biomol Ther (Seoul)", "NlmUniqueID": "101472832", "ISSNLinking": "1976-9148"}, "CoiStatement": "\n<b>CONFLICT OF INTEREST </b>\n. The authors have declared that there is no conflict of interest."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Bai L., Li A., Gong C., Ning X., Wang Z. Protective effect of rutin against bleomycin induced lung fibrosis: involvement of TGF-\u03b21/\u03b1-SMA/Col I and III pathway. BioFactors. 2020;46:637\u2013644. doi: 10.1002/biof.1629.", "ArticleIdList": ["10.1002/biof.1629", "32233122"]}, {"Citation": "Boyapally R., Pulivendala G., Bale S., Godugu C. Niclosamide alleviates pulmonary fibrosis in vitro and in vivo by attenuation of epithelial-to-mesenchymal transition, matrix proteins &Wnt/\u03b2-catenin signaling: a drug repurposing study. Life Sci. 2019;220:8\u201320. doi: 10.1016/j.lfs.2018.12.061.", "ArticleIdList": ["10.1016/j.lfs.2018.12.061", "30611787"]}, {"Citation": "Canestaro W. J., Forrester S. H., Raghu G., Ho L., Devine B. E. Drug treatment of idiopathic pulmonary fibrosis: systematic review and network meta-analysis. Chest. 2016;149:756\u2013766. doi: 10.1016/j.chest.2015.11.013.", "ArticleIdList": ["10.1016/j.chest.2015.11.013", "26836914"]}, {"Citation": "Chen C., Wang Y. Y., Wang Y. X., Cheng M. Q., Yin J. B., Zhang X., Hong Z. P. Gentiopicroside ameliorates bleomycin-induced pulmonary fibrosis in mice via inhibiting inflammatory and fibrotic process. Biochem. Biophys. Res. Commun. 2018;495:2396\u20132403. doi: 10.1016/j.bbrc.2017.12.112.", "ArticleIdList": ["10.1016/j.bbrc.2017.12.112", "29278701"]}, {"Citation": "Chen L., Zhao W. Apigenin protects against bleomycin-induced lung fibrosis in rats. Exp. Ther. Med. 2016;11:230\u2013234. doi: 10.3892/etm.2015.2885.", "ArticleIdList": ["10.3892/etm.2015.2885", "PMC4726877", "26889245"]}, {"Citation": "Chun-Bin S., Yi Y., Qin-Yi W., Yang L., Jing-Ze Y., Hai-Jing X., Si-Qi Z., Jiong H., Jing W., Fei-Yu L., Jin-Yuan Y., Jia-Li Y., Zhong-Shan Y. The main active components of Curcuma zedoaria reduces collagen deposition in human lung fibroblast via autophagy. Mol. Immunol. 2020;124:109\u2013116. doi: 10.1016/j.molimm.2020.05.017.", "ArticleIdList": ["10.1016/j.molimm.2020.05.017", "32554101"]}, {"Citation": "Cui Y., Jiang L., Yu R., Shao Y., Mei L., Tao Y. \u03b2-carboline alkaloids attenuate bleomycin induced pulmonary fibrosis in mice through inhibiting NF-kb/p65 phosphorylation and epithelial-mesenchymal transition. J. Ethnopharmacol. 2019;243:112096. doi: 10.1016/j.jep.2019.112096.", "ArticleIdList": ["10.1016/j.jep.2019.112096", "31323300"]}, {"Citation": "Divya T., Velavan B., Sudhandiran G. Regulation of transforming growth factor-\u03b2/Smad-mediated epithelial-mesenchymal transition by celastrol provides protection against bleomycin-induced pulmonary fibrosis. Basic Clin. Pharmacol. Toxicol. 2018;123:122\u2013129. doi: 10.1111/bcpt.12975.", "ArticleIdList": ["10.1111/bcpt.12975", "29394529"]}, {"Citation": "Dong S. H., Liu Y. W., Wei F., Tan H. Z., Han Z. D. Asiatic acid ameliorates pulmonary fibrosis induced by bleomycin (BLM) via suppressing pro-fibrotic and inflammatory signaling pathways. Biomed. Pharmacother. 2017;89:1297\u20131309. doi: 10.1016/j.biopha.2017.03.005.", "ArticleIdList": ["10.1016/j.biopha.2017.03.005", "28320097"]}, {"Citation": "Fu Y., Zhao P., Xie Z., Wang L., Chen S. Oridonin inhibits myofibroblast differentiation and bleomycin-induced pulmonary fibrosis by regulating transforming growth factor \u03b2 (TGF\u03b2)/Smad pathway. Med. Sci. Monit. 2018;24:7548\u20137555. doi: 10.12659/MSM.912740.", "ArticleIdList": ["10.12659/MSM.912740", "PMC6208186", "30347408"]}, {"Citation": "Garc\u00eda-Sancho C., Buend\u00eda-Rold\u00e1n, Fern\u00e1ndez-Plata M. R., Navarro C., P\u00e9rez-Padilla R., Vargas M. H., Loyd J. E., Selman M. Familial pulmonary fibrosis is the strongest risk factor for idiopathic pulmonary fibrosis. Respir. Med. 2011;105:1902\u20131907. doi: 10.1016/j.rmed.2011.08.022.", "ArticleIdList": ["10.1016/j.rmed.2011.08.022", "21917441"]}, {"Citation": "Gan C., Zhang Q., Liu H., Wang G., Wang L., Li Y., Tan Z., Yin W., Yao Y., Xie Y., Ouyang L., Yu L., Ye T. Nifuroxazide ameliorates pulmonary fibrosis by blocking myofibroblast genesis: a drug repurposing study. Respir Res. 2022;23:32. doi: 10.1186/s12931-022-01946-6.17651d1e590c4bfb8b43eaf44abeb2a7", "ArticleIdList": ["10.1186/s12931-022-01946-6", "PMC8848910", "35172837"]}, {"Citation": "Guan C., Qiao S., Lv Q., Cao N., Wang K., Dai Y., Wei Z. Orally administered berberine ameliorates bleomycin-induced pulmonary fibrosis in mice through promoting activation of PPAR-gamma and subsequent expression of HGF in colons. Toxicol. Appl. Pharmacol. 2018;343:1\u201315. doi: 10.1016/j.taap.2018.02.001.", "ArticleIdList": ["10.1016/j.taap.2018.02.001", "29408570"]}, {"Citation": "Gungor H., Ekici M., Onder Karayigit M., Turgut N. H., Kara H., Arslanbas E. Zingerone ameliorates oxidative stress and inflammation in bleomycin-induced pulmonary fibrosis: modulation of the expression of TGF-\u03b21 and iNOS. Naunyn-Schmiedeberg's Arch. Pharmacol. 2020;393:1659\u20131670. doi: 10.1007/s00210-020-01881-7.", "ArticleIdList": ["10.1007/s00210-020-01881-7", "32377772"]}, {"Citation": "Harari S., Caminati A. IPF: new insight on pathogenesis and treatment. Allergy. 2010;65:537\u2013553. doi: 10.1111/j.1398-9995.2009.02305.x.", "ArticleIdList": ["10.1111/j.1398-9995.2009.02305.x", "20121758"]}, {"Citation": "Iyer S. N., Gurujeyalakshmi G., Giri S. N. Effects of pirfenidone on transforming growth factor-\u03b2 gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J. Pharmacol. Exp. Ther. 1999;291:367\u2013373.", "ArticleIdList": ["10490926"]}, {"Citation": "Jiang F., Li M., Wang H., Ding B., Zhang C., Ding Z., Yu X., Lv G. Coelonin, an anti-inflammation active component of Bletilla striata and its potential mechanism. Int. J. Mol. Sci. 2019;20:4422. doi: 10.3390/ijms20184422.950daef0360b418aa89f6dc6cb52cc51", "ArticleIdList": ["10.3390/ijms20184422", "PMC6770560", "31500401"]}, {"Citation": "Karkale S., Khurana A., Saifi M. A., Godugu C., Talla V. Andrographolide ameliorates silica induced pulmonary fibrosis. Int. Immunopharmacol. 2018;62:191\u2013202. doi: 10.1016/j.intimp.2018.07.012.", "ArticleIdList": ["10.1016/j.intimp.2018.07.012", "30015239"]}, {"Citation": "King T. E., Jr., Bradford W. Z., Castro-Bernardini S., Fagan E. A., Glaspole I., Glassberg M. K., Gorina E., Hopkins P. M., Kardatzke D., Lancaster L., Lederer D. J., Nathan S. D., Pereira C. A., Sahn S. A., Sussman R., Swigris J. J., Noble P. W. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med. 2014;370:2083\u20132092. doi: 10.1056/NEJMoa1402582.", "ArticleIdList": ["10.1056/NEJMoa1402582", "24836312"]}, {"Citation": "Kreuter M., Bonella M., Wijsenbeek M., Maher T. M., Spagnolo P. Pharmacological treatment of idiopathic pulmonary fibrosis: current approaches, unsolved issues, and future perspectives. BioMed Res. Int. 2015;2015:329481. doi: 10.1155/2015/329481.", "ArticleIdList": ["10.1155/2015/329481", "PMC4686637", "26779535"]}, {"Citation": "Kropski J. A., Mitchell D. B., Markin C., Polosukhin V. V., Choi L., Johnson J. E., Lawson W. E., Phillips J. A., Cogan J. D., Blackwell T. S., Loyd J. E. A novel dyskerin (DKC1) mutation is associated with familial interstitial pneumonia. Chest. 2014;146:e1\u2013e7. doi: 10.1378/chest.13-2224.", "ArticleIdList": ["10.1378/chest.13-2224", "PMC4077414", "24504062"]}, {"Citation": "Kyung S. Y., Kim D. Y., Yoon J. Y., Son E. S., Kim Y. J., Park J. W., Jeong S. H. Sulforaphane attenuates pulmonary fibrosis by inhibiting the epithelial-mesenchymal transition. BMC Pharmacol.Toxicol. 2018;19:13. doi: 10.1186/s40360-018-0204-7.1f3254d53aa94f9ebb414eefe86a7991", "ArticleIdList": ["10.1186/s40360-018-0204-7", "PMC5879815", "29609658"]}, {"Citation": "Li C., Lu Y., Du S., Li S., Zhang Y., Liu F., Chen Y., Weng D., Chen J. Dioscin exerts protective effects against crystalline silica-induced pulmonary fibrosis in mice. Theranostics. 2017a;7:4255\u20134275. doi: 10.7150/thno.20270.", "ArticleIdList": ["10.7150/thno.20270", "PMC5695011", "29158824"]}, {"Citation": "Li C., Yu Y., Li W., Liu B., Jiao X., Song X., Lv C., Qin S. Phycocyanin attenuates pulmonary fibrosis via the TLR2-MyD88-NFkappaB signaling pathway. Sci. Rep. 2017b;7:5843. doi: 10.1038/s41598-017-06021-5.09c77f351b4d4181b4675adfb5cd1473", "ArticleIdList": ["10.1038/s41598-017-06021-5", "PMC5517415", "28725012"]}, {"Citation": "Li R. S., Xu G. H., Cao J., Liu B., Xie H. F., Ishii Y., Zhang C. F. \u03b1-Mangostin ameliorates bleomycin-induced pulmonary fibrosis in mice partly through activating adenosine 5'-monophosphate-activated protein kinase. Front. Pharmacol. 2019;10:1305. doi: 10.3389/fphar.2019.01305.25fefa79445c46e3a4f27e2f44e7e5d2", "ArticleIdList": ["10.3389/fphar.2019.01305", "PMC6863977", "31798444"]}, {"Citation": "Li X., Lu C., Liu S., Shuaishuai L., Su C., Xiao T., Bi Z., Sheng P., Huang M., Liu X., Wei Y., Zhao L., Miao S., Mao J., Huang K., Gao S., Liu N., Qi M., Liu T., Qin S., Wei L., Sun T., Ning W., Yang G., Zhou H., Yang C. Synthesis and discovery of a drug candidate for treatment of idiopathic pulmonary fibrosis through inhibition of TGF-\u03b21 pathway. Eur. J. Med. Chem. 2018a;157:229\u2013247. doi: 10.1016/j.ejmech.2018.07.074.", "ArticleIdList": ["10.1016/j.ejmech.2018.07.074", "30096654"]}, {"Citation": "Li X., Yu H., Liang L., Bi Z., Wang Y., Gao S., Wang M., Li H., Miao Y., Deng R., Ma L., Luan J., Li S., Liu M., Lin J., Zhou H., Yang C. Myricetin ameliorates bleomycin-induced pulmonary fibrosis in mice by inhibiting TGF-\u03b2 signaling via targeting HSP90\u03b2. Biochem. Pharmacol. 2020;178:114097. doi: 10.1016/j.bcp.2020.114097.", "ArticleIdList": ["10.1016/j.bcp.2020.114097", "32535102"]}, {"Citation": "Li X. H., Xiao T., Yang J. H., Qin Y., Gao J. J., Liu H. J., Zhou H. G. Parthenolide attenuated bleomycin-induced pulmonary fibrosis via the NF-kappaB/Snail signaling pathway. Respir. Res. 2018b;19:111. doi: 10.1186/s12931-018-0806-z.df33e8d6c02d49ccb89d15fcb8c0ed3b", "ArticleIdList": ["10.1186/s12931-018-0806-z", "PMC5989384", "29871641"]}, {"Citation": "Liu M., Xu H., Zhang L., Zhang C., Yang L., Ma E., Liu L., Li Y. Salvianolic acid B inhibits myofibroblast transdifferentiation in experimental pulmonary fibrosis via the up-regulation of Nrf2. Biochem. Biophys. Res. Commun. 2018;495:325\u2013331. doi: 10.1016/j.bbrc.2017.11.014.", "ArticleIdList": ["10.1016/j.bbrc.2017.11.014", "29108993"]}, {"Citation": "Loomis-King H., Flaherty K. R., Moore B. B. Pathogenesis, current treatments and future directions for idiopathic pulmonary fibrosis. Curr. Opin. Pharmacol. 2013;13:377\u2013385. doi: 10.1016/j.coph.2013.03.015.", "ArticleIdList": ["10.1016/j.coph.2013.03.015", "PMC3686907", "23602652"]}, {"Citation": "Ma H., Wu X., Li Y., Xia Y. Research progress in the molecular mechanisms, therapeutic targets, and drug development of idiopathic pulmonary fibrosis. Front. Pharmacol. 2022;13:963054. doi: 10.3389/fphar.2022.963054.9baaec58f210415fa7947253dbea17a4", "ArticleIdList": ["10.3389/fphar.2022.963054", "PMC9349351", "35935869"]}, {"Citation": "Maher T. M., Wells A. U., Laurent G. J. Idiopathic pulmonary fibrosis: multiple causes and multiple mechanisms? Eur. Respir. J. 2007;30:835\u2013839. doi: 10.1183/09031936.00069307.", "ArticleIdList": ["10.1183/09031936.00069307", "17978154"]}, {"Citation": "Mathai S. K., Schwartz D. A., Warg L. A. Genetic susceptibility and pulmonary fibrosis. Curr. Opin. Pulm. Med. 2014;20:429\u2013435. doi: 10.1097/MCP.0000000000000074.", "ArticleIdList": ["10.1097/MCP.0000000000000074", "PMC4337021", "25022318"]}, {"Citation": "Meltzer E. B., Noble P. W. Idiopathic pulmonary fibrosis. Orphanet J. Rare Dis. 2008;3:8. doi: 10.1186/1750-1172-3-8.4417f10628be48e2932b5fc5ca54f422", "ArticleIdList": ["10.1186/1750-1172-3-8", "PMC2330030", "18366757"]}, {"Citation": "Miao Y., Geng Y., Yang L., Zheng Y., Dai Y., Wei Z. Morin inhibits the transformation of fibroblasts towards myofibroblasts through regulating \"PPAR-\u03b3-glutaminolysis-DEPTOR\" pathway in pulmonary fibrosis. J. Nutr. Biochem. 2022;101:108923. doi: 10.1016/j.jnutbio.2021.108923.", "ArticleIdList": ["10.1016/j.jnutbio.2021.108923", "34843935"]}, {"Citation": "Miao K., Pan T., Mou Y., Zhang L., Xiong W., Xu Y., Yu J., Wang Y. Scutellarein inhibits BLM-mediated pulmonary fibrosis by affecting fibroblast differentiation, proliferation, and apoptosis. Ther. Adv. Chronic Dis. 2020;11:2040622320940185. doi: 10.1177/2040622320940185.1f1f0dcfe9344781a44a9f0826a84228", "ArticleIdList": ["10.1177/2040622320940185", "PMC7418478", "32843954"]}, {"Citation": "Nathan S. D., Albera C., Bradford W. Z., Costabel U., Glaspole I., Glassberg M. K., Kardatzke D., Daigl M., Kirchgaessler K.-U., Lancaster L., Leserer D. J., Pereira C. A., Swigris J. J., Valeyre D., Noble P. W. Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis. Lancet Respir. Med. 2017;5:33\u201341. doi: 10.1016/S2213-2600(16)30326-5.", "ArticleIdList": ["10.1016/S2213-2600(16)30326-5", "27876247"]}, {"Citation": "Noble P. W., Albera C., Bradford W. Z., Costabel U., Glassberg M. K., Kardatzke D., King T. E., Jr., Lancaster L., Sahn S. A., Szwarcberg J., Valeyre D., du Bois Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011;377:1760\u20131769. doi: 10.1016/S0140-6736(11)60405-4.", "ArticleIdList": ["10.1016/S0140-6736(11)60405-4", "21571362"]}, {"Citation": "Olson A. L., Swigris J. J. Idiopathic pulmonary fibrosis: diagnosis and epidemiology. Clin. Chest Med. 2012;33:41\u201350. doi: 10.1016/j.ccm.2011.12.001.", "ArticleIdList": ["10.1016/j.ccm.2011.12.001", "22365244"]}, {"Citation": "Sivashanmugam K., Kandasamy M., Subbiah R., Ravikumar Repurposing of histone deacetylase inhibitors: a promising strategy to combat pulmonary fibrosis promoted by TGF-\u03b2 signalling in COVID-19 survivors. Life Sci. 2021;266:118883. doi: 10.1016/j.lfs.2020.118883.", "ArticleIdList": ["10.1016/j.lfs.2020.118883", "PMC7831549", "33316266"]}, {"Citation": "Pardo A., Selman M. Idiopathic pulmonary fibrosis: new insights in its pathogenesis. Int. J. Biochem. Cell Biol. 2002;34:1534\u20131538. doi: 10.1016/S1357-2725(02)00091-2.", "ArticleIdList": ["10.1016/S1357-2725(02)00091-2", "12379275"]}, {"Citation": "Prashanth Goud M., Bale S., Pulivendala G., Godugu C. Therapeutic effects of Nimbolide, an autophagy regulator, in ameliorating pulmonary fibrosis through attenuation of TGF-\u03b21 driven epithelial-to-mesenchymal transition. Int. Immunopharmacol. 2019;75:105755. doi: 10.1016/j.intimp.2019.105755.", "ArticleIdList": ["10.1016/j.intimp.2019.105755", "31377591"]}, {"Citation": "Pulivendala G., Bale S., Godugu C. Honokiol: a polyphenol neolignan ameliorates pulmonary fibrosis by inhibiting TGF-\u03b2/Smad signaling, matrix proteins and IL-6/CD44/STAT3 axis both in vitro and in vivo. Toxicol. Appl. Pharmacol. 2020;391:114913. doi: 10.1016/j.taap.2020.114913.", "ArticleIdList": ["10.1016/j.taap.2020.114913", "32032644"]}, {"Citation": "Qian W., Cai X., Qian Q., Zhang W., Wang D. Astragaloside IV modulates TGF-\u03b21-dependent epithelial-mesenchymal transition in bleomycin-induced pulmonary fibrosis. J. Cell. Mol. Med. 2018;22:4354\u20134365. doi: 10.1111/jcmm.13725.", "ArticleIdList": ["10.1111/jcmm.13725", "PMC6111865", "29971947"]}, {"Citation": "Qu Y., Zhang G., Ji Y., Zhua H., Lv C., Jiang W. Protective role of gambogic acid in experimental pulmonary fibrosis in vitro and in vivo. Phytomedicine. 2016;23:350\u2013358. doi: 10.1016/j.phymed.2016.01.011.", "ArticleIdList": ["10.1016/j.phymed.2016.01.011", "27002405"]}, {"Citation": "Raghu G., Collard H. R., Egan J. J., Martinez F. J., Behr J., Brown K. K., Colby T. V., Cordier J.-F., Flaherty K. R., Lasky J. A., Lynch D. A., Ryu J. H., Swigris J. J., Wells A. U., Ancochea J., Bouros D., Carvalho C., Costabel U., Ebina M., Hansell D. M., Johkoh T., Kim D. S., King T. E., Jr., Kondoh Y., Myers J., M\u00fcller N. L., Nicholson A. G., Richeldi L., Selman M., Dudden R. F., Griss B. S., Protzko S. L., Sch\u00fcnemann H. J. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am. J. of Respir. Crit. Care Med. 2011;183:788\u2013824. doi: 10.1164/rccm.2009-040GL.", "ArticleIdList": ["10.1164/rccm.2009-040GL", "PMC5450933", "21471066"]}, {"Citation": "Richeldi L., Collard H. R., Jones M. G. Idiopathic pulmonary fibrosis. Lancet. 2017;389:1941\u20131952. doi: 10.1016/S0140-6736(17)30866-8.", "ArticleIdList": ["10.1016/S0140-6736(17)30866-8", "28365056"]}, {"Citation": "Richeldi L., du Bois R. M., Raghu G., Azuma A., Brown K. K., Costabel U., Cottin V., Flaherty K. R., Hansell D. M., Inoue Y., Kim D. S., Kolb M., Nicholson A. G., Noble P. W., Selman M., Taniguchi H., Brun M., Le Maulf F., Girard M., Stowasser S., Schlenker-Herceg R., Disse B., Collard H. R. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N. Engl. J. Med. 2014;370:2071\u20132082. doi: 10.1056/NEJMoa1402584.", "ArticleIdList": ["10.1056/NEJMoa1402584", "24836310"]}, {"Citation": "Selman M., King T. E., Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann. Intern. Med. 2001;134:136\u2013151. doi: 10.7326/0003-4819-134-2-200101160-00015.", "ArticleIdList": ["10.7326/0003-4819-134-2-200101160-00015", "11177318"]}, {"Citation": "Somogyi V., Chaudhuri N., Torrisi S. E., Kahn N., M\u00fcller V., Kreuter M. The therapy of idiopathic pulmonary fibrosis: what is next? Eur. Respir. Rev. 2019;28:190021. doi: 10.1183/16000617.0021-2019.9e2d2457e0fd4f09aae36eedb8bf99ea", "ArticleIdList": ["10.1183/16000617.0021-2019", "PMC9488691", "31484664"]}, {"Citation": "Sun S. C., Han R., Hou S. S., Yi H. Q., Chi S. J., Zhang A. H. Juglanin alleviates bleomycin-induced lung injury by suppressing inflammation and fibrosis via targeting sting signaling. Biomed. Pharmacother. 2020;127:110119. doi: 10.1016/j.biopha.2020.110119.", "ArticleIdList": ["10.1016/j.biopha.2020.110119", "32276127"]}, {"Citation": "Taniguchi H., Ebina M., Kondoh Y., Ogura T., Azuma A., Suga M., Taguchi Y., Takagashi H., Nakata K., Sato A., Takeuchi M., Raghu G., Kudoh S., Nukiwa T. Pirfenidone in idiopathic pulmonary fibrosis. Eur. Respir. J. 2010;35:21\u201329. doi: 10.1183/09031936.00005209.", "ArticleIdList": ["10.1183/09031936.00005209", "19996196"]}, {"Citation": "Tao L., Cao J., Wei W., Xie H., Zhang M., Zhang C. Protective role of rhapontin in experimental pulmonary fibrosis in vitro and in vivo. Int. Immunopharmacol. 2017;47:38\u201346. doi: 10.1016/j.intimp.2017.03.020.", "ArticleIdList": ["10.1016/j.intimp.2017.03.020", "28364627"]}, {"Citation": "Tian S. L., Yang Y., Liu X. L., Xu Q. B. Emodin attenuates bleomycin-induced pulmonary fibrosis via anti-inflammatory and anti-oxidative activities in rats. Med. Sci. Monit. 2018;24:1\u201310. doi: 10.12659/MSM.905496.", "ArticleIdList": ["10.12659/MSM.905496", "PMC5759514", "29290631"]}, {"Citation": "Travis W. D., Costabel U., Hansell D. M., King T. E., Lynch D., Nicholson A. G., Ryerson C. J., Ryu J. H., Selman M., Wells A. U., Behr J., Bouros D., Brown K. K., Colby T. V., Collard H. R., Cordeiro C. R., Cottin V., Crestani B., Drent M., Dudden R. F., Egan J., Flaherty K., Hogaboam C., Inoue Y., Johkoh T., Kim D. S., Kitaichi M., Loyd J., Martinez F. J., Myers J., Protzko S., Raghu G., Richeldi L., Sverzellati N., Swigris J., Valeyre D. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am. J. Respir. Crit. Care Med. 2013;188:733\u2013748. doi: 10.1164/rccm.201308-1483ST.", "ArticleIdList": ["10.1164/rccm.201308-1483ST", "PMC5803655", "24032382"]}, {"Citation": "Tzouvelekis A., Tzilas V., Dassiou M., Bouros D. Metformin in idiopathic pulmonary fibrosis \"seeking the holy-grail through drug-repositioning\". Respiration. 2018;96:305\u2013307. doi: 10.1159/000490917.", "ArticleIdList": ["10.1159/000490917", "30007987"]}, {"Citation": "Wang L., Liu H., He Q., Gan C., Li Y., Zhang Q., Yao Y., He F., Ye T., Yin W. Galangin ameliorated pulmonary fibrosis in vivo and in vitro by regulating epithelial-mesenchymal transition. Bioorg. Med. Chem. 2020a;28:115663. doi: 10.1016/j.bmc.2020.115663.", "ArticleIdList": ["10.1016/j.bmc.2020.115663", "32912432"]}, {"Citation": "Wang Y., Dong X., Zhao N., Su X., Wang Y., Li Y., Wen M., Li Z., Wang C., Chen J., Zuang W. Schisandrin B attenuates bleomycin-induced pulmonary fibrosis in mice through the wingless/integrase-1 signaling pathway. Exp. Lung Res. 2020b;46:185\u2013194. doi: 10.1080/01902148.2020.1760964.", "ArticleIdList": ["10.1080/01902148.2020.1760964", "32362157"]}, {"Citation": "Williams K. J. Gammaherpesviruses and pulmonary fibrosis: evidence from humans, horses, and rodents. Vet. Pathol. 2014;51:372\u2013384. doi: 10.1177/0300985814521838.", "ArticleIdList": ["10.1177/0300985814521838", "24569614"]}, {"Citation": "Wollin L., Wex E., Pautsch A., Schnapp G., Hostettler K. E., Stowasser S., Kolb M. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur. Respir. J. 2015;45:1434\u20131445. doi: 10.1183/09031936.00174914.", "ArticleIdList": ["10.1183/09031936.00174914", "PMC4416110", "25745043"]}, {"Citation": "Xia Y., Xia Y. F., Lv Q., Yue M. F., Qiao S. M., Yang Y., Wei Z. F., Dai Y. Madecassoside ameliorates bleomycin-induced pulmonary fibrosis in mice through promoting the generation of hepatocyte growth factor via PPAR-gamma in colon. Br. J. Pharmacol. 2016;173:1219\u20131235. doi: 10.1111/bph.13421.", "ArticleIdList": ["10.1111/bph.13421", "PMC5341335", "26750154"]}, {"Citation": "Yang F., Cao Y., Zhang J., You T., Zhu L. Glaucocalyxin A improves survival in bleomycin-induced pulmonary fibrosis in mice. Biochem. Biophys. Res. Commun. 2017;482:147\u2013153. doi: 10.1016/j.bbrc.2016.11.003.", "ArticleIdList": ["10.1016/j.bbrc.2016.11.003", "27816453"]}, {"Citation": "Yang H., Hua C., Yang X., Fan X., Song H., Peng L., Ci X. Pterostilbene prevents LPS-induced early pulmonary fibrosis by suppressing oxidative stress, inflammation and apoptosis in vivo. Food Funct. 2020;11:4471\u20134484. doi: 10.1039/C9FO02521A.", "ArticleIdList": ["10.1039/C9FO02521A", "32377661"]}, {"Citation": "Yang J. Y., Tao L. J., Liu B., You X. Y., Zhang C. F., Xie H. F., Li R. S. Wedelolactone attenuates pulmonary fibrosis partly through activating AMPK and regulating Raf-MAPKs signaling pathway. Front. Pharmacol. 2019;10:151. doi: 10.3389/fphar.2019.00151.f3835a5660bf467fa87045ff582c254b", "ArticleIdList": ["10.3389/fphar.2019.00151", "PMC6411994", "30890932"]}], "ReferenceList": []}], "History": [{"Year": "2023", "Month": "3", "Day": "14"}, {"Year": "2023", "Month": "4", "Day": "28"}, {"Year": "2023", "Month": "5", "Day": "10"}, {"Year": "2023", "Month": "5", "Day": "31", "Hour": "6", "Minute": "43"}, {"Year": "2023", "Month": "5", "Day": "31", "Hour": "6", "Minute": "42"}, {"Year": "2023", "Month": "5", "Day": "31", "Hour": "4", "Minute": "33"}, {"Year": "2023", "Month": "5", "Day": "31"}], "PublicationStatus": "ppublish", "ArticleIdList": ["37254717", "PMC10468426", "10.4062/biomolther.2023.056", "biomolther.2023.056"]}}], "PubmedBookArticle": []}